| 产品描述: | Berberine ursodeoxycholate (HTD1801) 是 Berberine 和 Ursodeoxycholic acid 的一种离子盐,是一种口服有效的降血脂剂 (hypolipidemic agent)。Berberine ursodeoxycholate 能显著降低肝脏脂肪含量。Berberine ursodeoxycholate 具有广泛的代谢活性。Berberine ursodeoxycholate 可用于高脂血症、非酒精性脂肪性肝炎 (NASH) 和糖尿病的研究。 |
| 体内研究: |
Berberine ursodeoxycholate shows significant reductions in HbA1c (hemoglobin A1c) levels, mean HbA1c levels decreases by 0.6%. Berberine ursodeoxycholate is ingested in the form of a salt and it is thought that the salt promptly dissociates within the gastrointestinal tract and that Berberine and Ursodeoxycholic acid are differentially absorbed. |
| 参考文献: |
1. Harrison SA, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503. 2. Di Bisceglie AM, et al. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis. 2020 Nov 12;19(1):239. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.374 ml |
6.869 ml |
13.738 ml |
| 5 mM |
0.275 ml |
1.374 ml |
2.748 ml |
| 10 mM |
0.137 ml |
0.687 ml |
1.374 ml |
| 50 mM |
0.027 ml |
0.137 ml |
0.275 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |